How many stocks are there of Zymeworks?
The current number of stocks of Zymeworks is 68.86 M undefined.
Zymeworks Stocks 2024
Zymeworks Stocks
68.86 M
Ticker
ZYME
ISIN
CA98985W1023
WKN
A2DP0F
In 2024, Zymeworks had 68.86 M outstanding stocks, a 0% change from the 68.86 M stocks in the previous year.
The Zymeworks Stocks history
| YEAR | NUMBER OF STOCKS (undefined USD) |
|---|---|
| 2029e | 68.86 |
| 2028e | 68.86 |
| 2027e | 68.86 |
| 2026e | 68.86 |
| 2025e | 68.86 |
| 2024e | 68.86 |
| 2023 | 68.86 |
| 2022 | 65.2 |
| 2021 | 51.6 |
| 2020 | 50.4 |
| 2019 | 38 |
| 2018 | 29.1 |
| 2017 | 21.2 |
| 2016 | 24.2 |
| 2015 | 24.2 |
| 2014 | 24.2 |
Zymeworks shares outstanding CA98985W1023 · A2DP0F
The number of shares was Zymeworks in 2023 — This indicates how many shares 68.863 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Zymeworks earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Zymeworks's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Zymeworks’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Zymeworks's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2014 | 24.2 M Aktien |
| 2015 | 24.2 M Aktien |
| 2016 | 24.2 M Aktien |
| 2017 | 21.2 M Aktien |
| 2018 | 29.1 M Aktien |
| 2019 | 38 M Aktien |
| 2020 | 50.4 M Aktien |
| 2021 | 51.6 M Aktien |
| 2022 | 65.2 M Aktien |
| 2023 | 68.86 M Aktien |
| 2024e | 68.86 M Aktien |
| 2025e | 68.86 M Aktien |
| 2026e | 68.86 M Aktien |
| 2027e | 68.86 M Aktien |
| 2028e | 68.86 M Aktien |
| 2029e | 68.86 M Aktien |
Zymeworks Aktienanalyse
What does Zymeworks do?
Zymeworks Inc is a biotechnology company that was founded in 2003. The company is headquartered in Vancouver, Canada. The founders of the company were a group of researchers specializing in the development of antibodies. Their goal was to develop a platform technology that allows for the design and production of highly specific and effective antibodies. Zymeworks Inc's platform technology is based on the use of protein engineering technologies such as Immunoglobulin G competences (IgG). This allows for the targeted production of antibodies that bind to specific target molecules. The business model of Zymeworks Inc is based on licensing its platform technology to other companies. The licensees use Zymeworks' platform to develop antibodies or other proteins for their own pharmaceutical research. Zymeworks Inc has various business areas that specialize in the different applications of its platform technology. This includes cancer immunotherapy, the treatment of autoimmune diseases, and the development of biological therapeutics. The company also offers products that can be used directly by patients, such as a test kit for determining the risk of breast cancer. Over the years, Zymeworks Inc has expanded its business areas and formed partnerships with major pharmaceutical companies. In summary, Zymeworks Inc is a leading biotechnology company specializing in the development of antibodies and other proteins. It has a unique platform technology that allows its customers to develop targeted antibodies and therapeutic proteins. Its products are used in various areas, including cancer immunotherapy, the treatment of autoimmune diseases, and biological therapeutics. Zymeworks ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating Zymeworks's Shares Outstanding
Zymeworks's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in Zymeworks’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding Zymeworks’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in Zymeworks’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about Zymeworks stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of Zymeworks are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of Zymeworks evolved in recent years?
The number of shares of Zymeworks has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. Zymeworks as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of Zymeworks?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does Zymeworks pay?
Over the past 12 months, Zymeworks paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Zymeworks is expected to pay a dividend of 0 USD.
What is the dividend yield of Zymeworks?
The current dividend yield of Zymeworks is .
When does Zymeworks pay dividends?
Zymeworks pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Zymeworks?
Zymeworks paid dividends every year for the past 0 years.
What is the dividend of Zymeworks?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Zymeworks located?
Zymeworks is assigned to the 'Health' sector.
Wann musste ich die Aktien von Zymeworks kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Zymeworks from 10/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/4/2024.
When did Zymeworks pay the last dividend?
The last dividend was paid out on 10/4/2024.
What was the dividend of Zymeworks in the year 2023?
In the year 2023, Zymeworks distributed 0 USD as dividends.
In which currency does Zymeworks pay out the dividend?
The dividends of Zymeworks are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Zymeworks
Our stock analysis for Zymeworks Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Zymeworks Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
